Oxford Immune Algorithmics (OIA) Secures a Coveted Spot in the UK Pavilion at The WORLD Expo 2020 in Dubai
The UK's Department of International Trade recently announced the selection of Oxford Immune Algorithmics (OIA) as one of the health-tech companies that will participate in the UK's Health Technology Showcase at Expo 2020. Companies were chosen based on "the most engaging, innovative and interesting healthcare solutions" presented. OIA's Algocyte mobile health device was recognised as one of Britain's top nine innovations in the Health and Life Science segment, from among submissions by forty health-tech companies. Oxford Immune Algorithmics are leaders in causal and model-driven AI and the creators of the Algocyte health-tech products.
The U.K. will lead in showcasing healthcare solutions that feature a multi-disciplinary approach to future healthcare needs. The Expo 2020 presentation could fundamentally alter the healthcare system, the patient journey, and immune diagnostics, both in the U.K. and beyond. OIA's Algocyte healthcare solution is one of nine innovations featured in the 'How Will We Thrive?' high-tech segment scheduled for January 29-30th. Oxford Immune Algorithmics and its flagship product, Algocyte, are honoured to be part of this historical event, which will showcase the best of Britain.
The UK Pavilion will feature the Inspiration Gallery, enveloping visitors in an interactive technological and sensory experience that combines architecture, science, artificial intelligence, art, and design. Four general areas will be explored and eight 'breakthrough moments' will be featured over the course of the 6-month long exhibition. The best of U.K. innovators will present what they consider sustainable, viable solutions to present and future challenges.
Expo is billed as the greatest global gathering in history and will feature the best ideas the world has to offer in technology, innovation, and the future. Dubai will host Expo 2020, the theme of which will be 'Connecting Minds, Creating the Future'. 191 countries are expected to participate. World leaders, dignitaries, top thinkers, and innovators will attend, with millions expected to visit the six-month long exhibition. The event occurs every five years, with participating countries presenting the best in science, culture, and innovation. Many new technological trends and future innovations make their debut here.
Expo 2020 will run from October 1, 2021 – March 31, 2022, with 191 countries participating and many millions of global citizens attending. Visitors will experience firsthand what is on the horizon and see how some of the world's most innovative minds are attempting to solve some of our most pressing challenges and thus shape the future.
Oxford Immune Algorithmics (OIA) is an award-winning Bio-Tech company incubated by the University of Oxford with a vision to democratise healthcare so as to rid the world of preventable diseases. To do this, OIA harnesses the power of an advanced type of augmented AI that has human-like reasoning capabilities to monitor people’s immune systems. OIA operates multi-nationally to build technology that moves healthcare away from its reliance on population-wide symptom pattern matching toward value-based precision medicine and personalised diagnostics.
Oxford Immune Algorithmics/Algocyte (OIA) CEO, Dr Hector Zenil is Appointed as Senior Researcher National Policy Advisor to U.K.’s Alan Turing Institute
The Alan Turing Institute, based in London, has appointed OIA's Founder and CEO, Dr Hector Zenil, as a senior researcher and policy advisor on Artificial Intelligence for Scientific Discovery. In this role, supported by the United States Department of Defense reporting to research officials at the Pentagon and the White House, Dr Zenil has been commissioned to lead and oversee the compilation of an international report to advise the U.K. and its allies on the use and future of A.I. in scientific discovery. Its particular focus will be A.I. capable of making scientific discoveries meriting a Nobel Prize in the next 30 years without the help of human scientists but with a view to accelerate science to find solutions to some of the most pressing human challenges, such as climate change, antibiotic resistance, cancer and chronic diseases.
Since 2016, Dr. Zenil co-leads the Algorithmic Dynamics Lab at the Unit of Computational Medicine at the Karolinska Institute in Sweden, the institution that awards the Nobel Prize in Physiology or Medicine. After joining the University of Oxford as senior researcher and faculty member, Dr. Zenil founded Oxford Immune Algorithmics (OIA). OIA are the creators of Algocyte, an AI solution that democratises healthcare by advancing precision and predictive medicine harnessing the power of responsible computational intelligence and the immune system.
Founded in 2015, the Alan Turing Institute is the United Kingdom's national data science and artificial intelligence institute. Named after Alan Turing, the British mathematician and computing pioneer, the institute is a joint venture among the Universities of Cambridge, Edinburgh, Oxford, Warwick and UCL. The Institute's Director and Chief Executive, appointed in 2018, is Sir Adrian Smith, who also serves as President of the Royal Society. The Chair of the Alan Turing Institute is Howard Covington.
Oxford Immune Algorithmics (OIA) is an award-winning Bio-Tech company incubated by the University of Oxford with a vision to democratise healthcare so as to rid the world of preventable diseases. To do this, OIA harnesses the power of an advanced type of augmented AI that has human-like reasoning capabilities to monitor people’s immune systems. OIA operates multi-nationally to build technology that moves healthcare away from its reliance on population-wide symptom pattern matching toward value-based precision medicine and personalised diagnostics